Literature DB >> 15003901

Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

Giovanni Martinelli1, Michele Malagola, Emanuela Ottaviani, Gianantonio Rosti, Elena Trabacchi, Michele Baccarani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15003901

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  3 in total

1.  Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment.

Authors:  Nur Selvi; Burçin Tezcanlı Kaymaz; Handan Haydaroğlu Sahin; Mustafa Pehlivan; Cağdaş Aktan; Ayşegül Dalmızrak; Ezgi Inalpolat; Buket Kosova; Mehmet Yılmaz; Vahap Okan; Güray Saydam
Journal:  Mol Biol Rep       Date:  2012-10-18       Impact factor: 2.316

Review 2.  Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Authors:  Ayalew Tefferi; Animesh Pardanani
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

3.  Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy.

Authors:  Yasuhiro Tanaka; Masayuki Kurata; Katsuhiro Togami; Haruyuki Fujita; Naoko Watanabe; Akiko Matsushita; Akinori Maeda; Kenichi Nagai; Akiko Sada; Toshimitsu Matsui; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.